



17 April 2013

Dear Option holder

**Share Purchase Plan – option holders' participation**

---

**Novogen Ltd (ASX: NRT)** today announced its Share Purchase Plan (SPP), which gives eligible shareholders the opportunity to purchase up to \$15,000 worth of Novogen's ordinary shares without incurring brokerage or transaction costs.

Only Australian and New Zealand investors who were recorded on the share register as shareholders at 7.00pm on the record date of 16 April 2013 (**Record Date**) are entitled to participate in the SPP offer. The Record Date is specified in accordance with the ASX Listing Rules.

The SPP, including eligibility, is subject to the more detailed SPP rules which prevail to the extent of any inconsistency.

The holding of options does not confer a right to participate in the SPP.


If you have any questions about your entitlement to participate in the SPP, please contact our share registry.

The share registry contact details are:

Computershare Investor Services Pty Limited  
Level 4, 60 Carrington Street, Sydney NSW 2000  
Tel: 1300 855 080 (within Australia) and +61 3 9415 4000 (outside Australia)

Novogen thanks you for your support of the Company.

Yours faithfully



Graham Kelly  
Executive Chairman

**For further information contact:**

Graham Kelly  
Executive Chairman  
Novogen Ltd  
Telephone: 0459 200 095

Email: [Graham.Kelly@novogen.com](mailto:Graham.Kelly@novogen.com)

Website: [www.novogen.com](http://www.novogen.com)

### **About Novogen Ltd:**

Novogen Ltd is a public Australian biotechnology company whose shares trade on both the Australian Stock Exchange (symbol 'NRT') and NASDAQ (symbol 'NVGN'). The Company is based in Sydney, Australia and is focused on the development of a family of novel anti-cancer drugs based on super-benzopyran and 'stealth' drug technologies. The Company's inaugural drug candidate is CS-6.

### **About CS-6**

CS-6 belongs to a new class of drug candidates known (structurally) as super-benzopyrans displaying potent anti-cancer activity and demonstrating increased bio-availability to cancer cells ('stealth' technology). CS-6 shows broad anti-proliferative and cytotoxic activity against human cancer cells, with particular activity against human glioblastoma cells. CS-6 also has been designed deliberately to meet the major known criteria for crossing the blood-brain barrier, and for that reason is being developed as a first-line for the treatment of glioblastoma multiforme, the main form of primary brain cancer.

**More information:** [www.novogen.com](http://www.novogen.com)

### **Safe harbour statement**

Certain statements made in this document and material referred to in this document that use the words "estimate", "project", "intend", "expect", "believe" and similar expressions are intended to identify forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (U.S.). These forward looking statements involve known and unknown risks and uncertainties which could cause the actual results, performance or achievements of the company to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties that could change the results described in the forward-looking statements.

Investors should be aware that there are no assurances that results will not differ from those projected.